Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carcinoma of the Lungs”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00412880
What this trial is testing

BI 2536 Second Line Monotherapy in SCLC

Who this might be right for
Carcinoma, Small Cell
Boehringer Ingelheim 23
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Looking for participantsNCT05797168
What this trial is testing

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Who this might be right for
Ovarian CancerLung AdenocarcinomaEndometrial Cancer+1 more
AstraZeneca 602
Not applicableStudy completedNCT04732520
What this trial is testing

Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Galvanize Therapeutics, Inc. 47
Testing effectiveness (Phase 2)Study completedNCT03371979
What this trial is testing

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Who this might be right for
Small-cell Lung Cancer
Aeglea Biotherapeutics 68
Testing effectiveness (Phase 2)UnknownNCT05228496
What this trial is testing

Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Who this might be right for
Lung Cancer, Small Cell
Zhejiang Cancer Hospital 21
Not applicableLooking for participantsNCT06494540
What this trial is testing

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Who this might be right for
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca 600
Testing effectiveness (Phase 2)Looking for participantsNCT07120282
What this trial is testing

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Large-scale testing (Phase 3)Study completedNCT01040780
What this trial is testing

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 399
Testing effectiveness (Phase 2)Active Not RecruitingNCT02716116
What this trial is testing

TAK-788 in Adults With Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Takeda 334
Early research (Phase 1)Study completedNCT04069026
What this trial is testing

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Who this might be right for
Advanced Solid Tumors
Bayer 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06882174
What this trial is testing

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

Who this might be right for
Metastatic Non Small Cell Lung Cancer
AHS Cancer Control Alberta 58
Large-scale testing (Phase 3)Ended earlyNCT00054210
What this trial is testing

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
CTI BioPharma
Large-scale testing (Phase 3)UnknownNCT04964479
What this trial is testing

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 375
Testing effectiveness (Phase 2)Active Not RecruitingNCT05796089
What this trial is testing

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Who this might be right for
Extensive-Stage Small-Cell Lung Cancer
Trans Tasman Radiation Oncology Group 35
Testing effectiveness (Phase 2)Study completedNCT00098085
What this trial is testing

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung CarcinomaLung CancerPulmonary Cancer
Agenus Inc. 20
Testing effectiveness (Phase 2)Ended earlyNCT00321308
What this trial is testing

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell Lung
Pfizer 36
Testing effectiveness (Phase 2)Study completedNCT01259089
What this trial is testing

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Who this might be right for
Adenocarcinoma of the LungNon-small Cell Lung Cancer
Northwestern University 38
Testing effectiveness (Phase 2)Looking for participantsNCT06918132
What this trial is testing

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell CarcinomaStage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8+2 more
Mayo Clinic 60
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Next Page